Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a…

Overview of attention for article published in Lancet Infectious Diseases, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 16 news outlets
twitter: 49 X users
patent: 2 patents

reddit: 1 Redditor
bluesky: 1 Bluesky user

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 17 news stories from 16 outlets.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva VLA2001 - Ganzvirus-Impfstoff für Erwachsene

Ad Hoc News, 19 Sep 2026

COVID-19 Vaccine (inactivated, adjuvanted) Valneva (VLA2001) ist ein inaktivierter Ganzvirus-COVID-19-Impfstoff für Erwachsene…

Valneva Publishes Trial Results for Inactivated, Whole-Virus COVID-19 Vaccine

Contagion Live , 07 Sep 2022

Yesterday, Valneva announced the publication of phase 3 data for their COVID-19 vaccine candidate, VLA2001.

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

Spoke, 06 Sep 2022

Saint-Herblain (France), September 6, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today…

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

VB Profiles, 06 Sep 2022

Saint-Herblain (France), September 6, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.